Jefferies Group LLC reiterated their buy rating on shares of Horizon Pharma PLC (NASDAQ:HZNP) in a report published on Wednesday. They currently have a $16.00 price objective on the biopharmaceutical company’s stock.

Other analysts also recently issued reports about the stock. UBS AG set a $16.00 target price on shares of Horizon Pharma PLC and gave the stock a buy rating in a report on Tuesday, August 8th. Piper Jaffray Companies set a $18.00 target price on shares of Horizon Pharma PLC and gave the stock a buy rating in a report on Monday, August 7th. BidaskClub upgraded shares of Horizon Pharma PLC from a hold rating to a buy rating in a report on Saturday, June 24th. Cantor Fitzgerald set a $13.00 target price on shares of Horizon Pharma PLC and gave the stock a buy rating in a report on Monday, July 31st. Finally, BMO Capital Markets restated a buy rating and set a $17.00 target price on shares of Horizon Pharma PLC in a report on Friday, July 28th. Five investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. The company has an average rating of Buy and a consensus price target of $18.00.

Shares of Horizon Pharma PLC (NASDAQ:HZNP) traded up 1.12% on Wednesday, reaching $12.68. 2,645,825 shares of the company were exchanged. Horizon Pharma PLC has a 12 month low of $9.45 and a 12 month high of $21.98. The stock has a 50 day moving average price of $12.81 and a 200-day moving average price of $12.94. The stock’s market capitalization is $2.07 billion.

Horizon Pharma PLC (NASDAQ:HZNP) last announced its earnings results on Monday, August 7th. The biopharmaceutical company reported $0.41 EPS for the quarter, topping the consensus estimate of $0.12 by $0.29. The firm had revenue of $289.51 million for the quarter, compared to the consensus estimate of $237.01 million. Horizon Pharma PLC had a negative net margin of 42.40% and a positive return on equity of 22.85%. The business’s quarterly revenue was up 12.5% on a year-over-year basis. During the same period last year, the company posted $0.56 EPS. On average, equities analysts expect that Horizon Pharma PLC will post $1.07 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Horizon Pharma PLC (HZNP) Earns “Buy” Rating from Jefferies Group LLC” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another publication, it was copied illegally and reposted in violation of international trademark & copyright law. The legal version of this story can be accessed at https://www.thecerbatgem.com/2017/09/30/horizon-pharma-plc-hznp-earns-buy-rating-from-jefferies-group-llc.html.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Profund Advisors LLC raised its holdings in shares of Horizon Pharma PLC by 0.8% in the first quarter. Profund Advisors LLC now owns 13,508 shares of the biopharmaceutical company’s stock valued at $200,000 after purchasing an additional 112 shares during the last quarter. US Bancorp DE grew its stake in shares of Horizon Pharma PLC by 1.2% in the first quarter. US Bancorp DE now owns 32,050 shares of the biopharmaceutical company’s stock valued at $473,000 after buying an additional 368 shares in the last quarter. Prudential Financial Inc. grew its stake in shares of Horizon Pharma PLC by 2.6% in the first quarter. Prudential Financial Inc. now owns 16,680 shares of the biopharmaceutical company’s stock valued at $247,000 after buying an additional 420 shares in the last quarter. Sheaff Brock Investment Advisors LLC grew its stake in shares of Horizon Pharma PLC by 5.0% in the second quarter. Sheaff Brock Investment Advisors LLC now owns 10,500 shares of the biopharmaceutical company’s stock valued at $125,000 after buying an additional 500 shares in the last quarter. Finally, Amalgamated Bank grew its stake in shares of Horizon Pharma PLC by 4.8% in the second quarter. Amalgamated Bank now owns 20,711 shares of the biopharmaceutical company’s stock valued at $246,000 after buying an additional 943 shares in the last quarter. Institutional investors own 82.30% of the company’s stock.

Horizon Pharma PLC Company Profile

Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.

Analyst Recommendations for Horizon Pharma PLC (NASDAQ:HZNP)

Receive News & Stock Ratings for Horizon Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma PLC and related stocks with our FREE daily email newsletter.